DICE Therapeutics
Felice Ng, CPA has a diverse work experience in the field of accounting. Felice currently works as an Accountant at DICE Therapeutics since November 2022. Prior to that, they served as a Senior Accountant at Westlake Realty Group from February 2020 to November 2022.
Between 2016 and 2020, Felice held multiple roles at MidPen Housing Corporation. Felice started as a Property Accountant in July 2016 and later transitioned to become a Development Accountant in May 2018. During this period, they gained valuable experience in managing financials for property development and management.
Earlier in their career, Felice worked as a Staff Accountant at the Low Income Investment Fund from August 2015 to July 2016. Felice also held similar positions at Tiret and Company, CPAS from June 2013 to August 2015, and Fong, Ko and Associates, LLP from February 2013 to June 2013.
Overall, Felice Ng's work experience highlights their expertise in accounting and their ability to adapt to various roles and responsibilities in different organizations.
Felice Ng, CPA, holds a Bachelor of Business Administration (B.B.A.) degree in Accounting from California State University East Bay, which they obtained from 2009 to 2011. Prior to that, they studied Clothing Technology at the University of the Philippines, where they earned a Bachelor of Science (BS) degree. In 2014, Felice obtained their certification as a Certified Public Accountant.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.